Novo Nordisk Expands Indian Operations, Partners with AI Startups to Enhance Drug Development

Novo Nordisk's Strategic Expansion in India

Danish pharmaceutical giant Novo Nordisk, renowned for its weight-loss drug Wegovy, is significantly expanding its operations in India. The company is leveraging the country's burgeoning AI ecosystem and talent pool to enhance its global drug development processes 1

1

Partnerships with Indian AI Startups

Novo Nordisk has forged partnerships with 10 Indian AI startups to streamline its operations. These collaborations focus on utilizing AI tools for various tasks, including:

1. Summarizing documents
2. Extracting insights
3. Checking for editing errors

John Dawber, Novo's managing director for global business services, revealed that some of these AI tools are being implemented across the company's global operations 2

2

Enhancing Efficiency with AI

The integration of AI has led to significant improvements in efficiency:

• Medical writers now use AI to reduce quality check times on regulatory documents from 40 hours to about 40 minutes per document 3

  3

  .
• Half of Novo's global safety assessment work, which tracks drug side effects, is handled by its India operation.

Expansion of Indian Operations

Novo Nordisk's Bengaluru center, established 17 years ago, is set for substantial growth:

• The company plans to double the number of "global process leaders" based in India over the next 3-4 years.
• Overall headcount in India is expected to increase by 16% to 5,000 employees by next year.
• The Bengaluru center is projected to become "an almost perfect mirror image" of Novo's Denmark headquarters in terms of handling R&D data within three years 2

  2

  .

Related Stories

Novo Nordisk partners with OpenAI to accelerate drug discovery and obesity treatment development

Eli Lilly strikes $2.75 billion deal with Insilico Medicine to accelerate AI drug development

Nestle uses AI to create products for weight-loss drugs like Ozempic and Wegovy

Eli Lilly Signs $1.3 Billion AI-Driven Deal with Superluminal for Obesity Drug Discovery

India's Growing Importance in Pharma R&D

Novo Nordisk's expansion aligns with a broader trend of pharmaceutical companies investing in India:

• Sanofi plans to invest $437 million in its India center.
• Bristol Myers Squibb expects its Hyderabad facility to become its largest unit outside the U.S. by 2025, focusing on AI and digital technologies for drug development 3

  3

  .

Future Prospects

As Novo Nordisk and Eli Lilly compete in the global weight-loss market, potentially worth $150 billion in the next decade, their expansion in India could play a crucial role. Both companies have plans to launch their GLP-1 receptor agonist drugs in India, further emphasizing the country's importance in their global strategies 1

1